Get the Stockscreener App
11.97
0.50%
-0.06
After Hours:
11.97
Elanco Animal Health Inc stock is traded at $11.97, with a volume of 7.13M.
It is down -0.50% in the last 24 hours and up +0.42% over the past month.
Elanco Animal Health is an animal health company that is engaged in developing, manufacturing, and marketing pharma products for companion and food animals. It spun off from Eli Lilly in 2018 and acquired Janssen Animal Health in 2011, Novartis Animal Health in 2014, Boehringer Ingelheim Vetmedica in 2017, and Bayer Animal Health in 2020. The company's operations are conducted globally, and it sells its products in over 90 countries. It offers a range of food animal products used in cattle, sheep, goats, and swine production.
See More
Previous Close:
$12.03
Open:
$12.1
24h Volume:
7.13M
Relative Volume:
1.53
Market Cap:
$5.92B
Revenue:
$4.45B
Net Income/Loss:
$205.00M
P/E Ratio:
29.93
EPS:
0.4
Net Cash Flow:
$372.00M
1W Performance:
-4.01%
1M Performance:
+0.42%
6M Performance:
-3.86%
1Y Performance:
-25.28%
1-Day Range:
$11.88
$12.14
1-Week Range:
$11.39
$12.47
52-Week Range:
$11.11
$18.80
Elanco Animal Health Inc Stock (ELAN) Company Profile
Name
Elanco Animal Health Inc
Sector
Phone
877-352-6261
Address
2500 INNOVATION WAY, GREENFIELD
Compare ELAN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ELAN
Elanco Animal Health Inc
|
11.97 | 5.92B | 4.45B | 205.00M | 372.00M | 0.40 |
|
ZTS
Zoetis Inc
|
174.12 | 78.56B | 9.15B | 2.43B | 2.31B | 5.32 |
|
TAK
Takeda Pharmaceutical Co Adr
|
13.61 | 43.15B | 30.25B | 1.37B | 5.08B | 0.4257 |
|
HLN
Haleon Plc Adr
|
9.51 | 43.00B | 14.26B | 1.55B | 0 | 0.3383 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.29 | 19.59B | 16.54B | -1.64B | 749.00M | -1.45 |
|
NBIX
Neurocrine Biosciences Inc
|
150.51 | 15.24B | 2.24B | 385.90M | 440.10M | 3.73 |
Elanco Animal Health Inc Stock (ELAN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-09-24 | Initiated | UBS | Buy |
| Dec-02-24 | Initiated | Leerink Partners | Market Perform |
| Sep-19-24 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-05-24 | Upgrade | Stifel | Hold → Buy |
| Dec-19-23 | Initiated | Jefferies | Buy |
| Dec-15-23 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Dec-07-23 | Initiated | Exane BNP Paribas | Outperform |
| Apr-20-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Aug-18-22 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Aug-16-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-21-22 | Downgrade | Goldman | Buy → Sell |
| Jul-12-22 | Initiated | Piper Sandler | Neutral |
| Nov-18-21 | Initiated | Morgan Stanley | Overweight |
| Oct-28-21 | Downgrade | Stifel | Buy → Hold |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jun-15-21 | Upgrade | Cleveland Research | Underperform → Neutral |
| May-11-21 | Upgrade | Barclays | Underweight → Equal Weight |
| May-11-21 | Upgrade | Gabelli & Co | Hold → Buy |
| Apr-15-21 | Initiated | Stifel | Buy |
| Mar-22-21 | Downgrade | Gabelli & Co | Buy → Hold |
| Feb-26-21 | Upgrade | Credit Suisse | Neutral → Outperform |
| Dec-09-20 | Downgrade | Argus | Buy → Hold |
| Nov-09-20 | Downgrade | Barclays | Overweight → Underweight |
| Aug-20-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Aug-13-20 | Resumed | Credit Suisse | Neutral |
| Aug-04-20 | Resumed | Goldman | Buy |
| Jul-27-20 | Downgrade | Cleveland Research | Neutral → Underperform |
| Apr-02-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jan-10-20 | Initiated | Raymond James | Mkt Perform |
| Dec-19-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Nov-07-19 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Sep-23-19 | Initiated | Barclays | Overweight |
| Aug-26-19 | Downgrade | BofA/Merrill | Buy → Neutral |
| Aug-15-19 | Upgrade | UBS | Sell → Neutral |
| May-23-19 | Initiated | Guggenheim | Neutral |
| Mar-18-19 | Upgrade | BofA/Merrill | Neutral → Buy |
| Mar-13-19 | Resumed | Morgan Stanley | Equal-Weight |
| Feb-12-19 | Initiated | William Blair | Mkt Perform |
| Jan-23-19 | Initiated | UBS | Sell |
| Jan-15-19 | Initiated | Argus | Buy |
| Oct-15-18 | Initiated | Morgan Stanley | Equal-Weight |
View All
Elanco Animal Health Inc Stock (ELAN) Latest News
Veterinary Wound Cleansers Market Share & Growth Forecast Report 2025-2030, with Elanco, Vetoquinol, Virbac, Innovacyn, Axio Biosolutions, Neogen, Pet Natural Remedies, Zoetis and More - Yahoo Finance UK
Private Management Group Inc. Acquires 914,808 Shares of Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
Animal Parasiticides Market Witness Growth: Size, Share, - openPR
Elanco Launches Pradalex for Treatment of Livestock Respiratory Diseases - Drovers Magazine
Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - Markets Insider
BlackRock, Inc.'s Strategic Acquisition of Elanco Animal Health Inc Shares - GuruFocus.com
Elanco launches novel treatment for livestock respiratory diseases - Feedstuffs
Pet Pharmaceuticals Market Growth to Accelerate in Forecast - openPR
Elanco Animal Health Incorporated (NYSE:ELAN) Shares Acquired by KBC Group NV - MarketBeat
Elanco Confirms Date and Conference Call for Fourth Quarter and Full Year 2024 Financial Results Announcement - Nasdaq
Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Stockholders to Connect - Markets Insider
Jim Cramer on Elanco Animal Health Incorporated (ELAN): ‘Not My Favorite’ - Insider Monkey
Elanco Animal Health (NYSE:ELAN) Given New $14.00 Price Target at Morgan Stanley - MarketBeat
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Stockholders to Learn More About the Investigation - Markets Insider
Elanco Animal demitasse Health Incorporated - The Branding Iron
US FDA approves Elanco's treatment for parasitic infections in dogs - AOL
Veterinary Medicine Market Is Booming Worldwide 2025-2032 | - openPR
Elanco price target lowered to $14 from $15 at Morgan Stanley - MSN
2025-01-29 | Bronstein, Gewirtz & Grossman, LLC Encourages Elanco Animal Health Incorporated (ELAN) Shareholders to Inquire about Securities Investigation | NYSE:ELAN | Press Release - Stockhouse Publishing
ELAN SHAREHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Elanco Animal Health Incorporated and Urges Investors to Contact the Firm Today! - ACCESS Newswire
Meet the Faces of Zen: Elanco's Zenrelia™ (ilunocitinib tablets) Helps Allergic Dogs Get Back to Normal - PR Newswire
2025-01-26 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Shareholders to Connect | NYSE:ELAN | Press Release - Stockhouse Publishing
Senior, geriatric dog care focus of new industry partnership - VeterinaryPracticeNews.com
Animal Gastroesophageal Reflux Disease Market Analysis Report 2025-2030, with Profiles of Key Players Zoetis, Merck, Elanco, Ceva, BioZyme, Annamaet Petfoods, Hill's Pet Nutrition, Blue Buffalo & More - Yahoo Finance
Now Available: Credelio Quattro™ (lotilaner, moxidectin, praziquantel, and pyrantel chewable tablets) Provides Broadest[i] Parasite Protection of Its Kind - PR Newswire
Assenagon Asset Management S.A. Sells 1,369,833 Shares of Elanco Animal Health Incorporated (NYSE:ELAN) - MarketBeat
2025-01-22 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Elanco Animal Health Incorporated (ELAN) And Encourages Shareholders to Reach Out | NYSE:ELAN | Press Release - Stockhouse Publishing
Jim Cramer: AMD Is A 'Great' Company, Hold Onto Dow Inc. - Benzinga
UK Veterinary Medicine Market May See a Big Move | Norbrook, Merck, Elanco - openPR
Is Elanco Animal Health Incorporated (ELAN) the Most Undervalued Stock to Invest in for Under $20? - Insider Monkey
12 Most Undervalued Stocks to Invest in for Under $20 - Insider Monkey
Top animal health companies by revenue worldwide 2023 - Statista
2025-01-19 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Elanco Animal Health Incorporated (ELAN) and Encourages Investors to Learn More About the Investigation | NYSE:ELAN | Press Release - Stockhouse Publishing
ELAN (Elanco Animal Health) Deferred Tax : $0 Mil (TTM As of Sep. 2024) - GuruFocus.com
Elanco Animal Health's SWOT analysis: stock outlook amid product challenges - MSN
ELAN (Elanco Animal Health) Long-Term Debt : $4,313 Mil (As of Sep. 2024) - GuruFocus.com
Elanco Animal Health’s SWOT analysis: stock outlook amid product challenges - Investing.com Nigeria
Companion Animal Ear Infection Treatment Market SWOT Analysis by Leading Expert: Elanco, Vetoquinol, Ceva - openPR
2025-01-15 | Elanco Animal Health Incorporated (ELAN) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NYSE:ELAN | Press Release - Stockhouse Publishing
Elanco Animal Health: Building On Success (NYSE:ELAN) - Seeking Alpha
Veterinary Vaccines Market SWOT Analysis by Leading Expert: Virbac, Elanco, HIPRA - openPR
ELAN (Elanco Animal Health) Change In Working Capital : $239 Mil (TTM As of Sep. 2024) - GuruFocus.com
2025-01-12 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Elanco Animal Health Incorporated (ELAN) And Encourages Investors to Connect | NYSE:ELAN | Press Release - Stockhouse Publishing
Is Elanco Animal Health (ELAN) the Best Medical Stock to Buy Under $20? - Insider Monkey
12 Best Medical Stocks To Buy Under $20 - Insider Monkey
Elanco Animal Health Inc Stock (ELAN) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.51%
0.25%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):